Top Medical News
ADHD medication use carries no excess risk of cardiovascular diseases
Users of attention-deficit/hyperactivity disorder (ADHD) medications across age groups do not appear to be at increased risk of cardiovascular diseases (CVDs), although a modest risk increase of cardiac arrest or tachyarrhythmias could not be ruled out, according to the results of a meta-analysis.
Pharmacogenomic profiling of paediatric AML informs precision medicine
Natalia Reoutova, Yesterday

A study by the Chinese University of Hong Kong (CUHK) has found age-specific differences in drug responses and new gene-drug interactions in paediatric acute myeloid leukaemia (AML).

Intermittent fasting may not be healthy after all
Elvira Manzano, 4 days ago
Currently in vogue, intermittent fasting (IF) – which switches between periods of eating and fasting – may not be as beneficial as many have thought.
High-flow nasal cannula oxygen therapy better than CPAP in preterm infants
Tristan Manalac, 4 days ago
Compared with continuous positive airway pressure (CPAP), respiratory support using high-flow nasal cannula oxygen therapy (HNFC) appears to yield better clinical outcomes in preterm infants, according to a recent meta-analysis.
C-reactive protein levels unrelated to spinal pain in kids
4 days ago
There appears to be no link between C-reactive protein (CRP) levels and the trajectory of spinal pain in children and adolescents, a recent study has found.
CGM improves HbA1c levels in T1D
Roshini Claire Anthony, 5 days ago

Continuous glucose monitoring (CGM) with alarms for high or low blood sugar levels better controlled HbA1c levels than personal fingerstick monitoring in patients with type 1 diabetes (T1D), results of the FLASH-UK trial showed.

Nailfold abnormality ups calcinosis risk in juvenile dermatomyositis
26 Nov 2022
Children with idiopathic inflammatory myopathies who present with abnormal nailfold capillary changes at baseline are prone to the development of calcinosis, suggests a recent study.
Special Reports
Product Highlight - Bilaxten ODT
16 Mar 2022
Bilastine 10 mg orodispersible tablet
Kids hard-hit by Delta; which ART performs best?
Elvira Manzano, 24 Oct 2021
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
ID NOW rapid molecular assay an effective COVID-19 test for kids
Roshini Claire Anthony, 20 Oct 2021

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Combined Ag/Ab rapid testing boosts case-finding in COVID-19
Elvira Manzano, 29 Jul 2021
A rapid and affordable test for diagnosing COVID-19 outside the walls of the healthcare units could improve case-finding, contact tracing, and infection control, says an expert during a pre-ECCMID 2021 session.
Product Highlight - Zinforo
16 Jun 2021
Ceftaroline fosamil 600 mg powder for infusion
Navigating the CPP patient journey – case-based discussion for nurses
06 May 2021
In a webinar held on 27 March 2021, paediatric endocrinology nurses Karen Blair, Kate Davies, and Siti Zarina Yaakop shared insights and clinical experience based on their frontline roles in caring for patients with central precocious puberty (CPP) and supporting their family members.
A Guide on Primary Immunodeficiency Disease and Allergies
05 Feb 2021

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.

Conference Reports
Skin biomarkers predict AD risk, severity in newborns
Elvira Manzano, 27 Oct 2022
Predicting which newborn will go on to develop atopic dermatitis (AD) and how severe it will be is now feasible, according to the BABY* study.
Ruxolitinib improves repigmentation in vitiligo through 52 weeks
Elaine Soliven, 21 Oct 2022
Long-term use of ruxolitinib cream continued to improve facial and total body repigmentation in patients with nonsegmental vitiligo from 24 to 52 weeks, according to an updated pooled analysis of the phase III TRuE-V1* and TRuE-V2** studies presented at EADV 2022.
Lebrikizumab efficacy in atopic dermatitis maintained at 1 year
Roshini Claire Anthony, 12 Oct 2022

Maintenance lebrikizumab monotherapy appears to improve outcomes in patients with moderate-to-severe atopic dermatitis (AD), according to results of the phase III ADvocate1 and ADvocate2 trials.

ALLEGRO-LT shows long-term benefit of ritlecitinib for alopecia areata
Audrey Abella, 21 Sep 2022
In the interim analysis of the ongoing phase III ALLEGRO-LT trial, the investigational oral JAK3*/TEC inhibitor ritlecitinib demonstrated long-term safety and remarkable scalp hair regrowth in adults and adolescents with alopecia areata (AA).
Similar asthma outcomes, but higher allergy rates, in ART-conceived children
Elaine Soliven, 11 Aug 2022
Children conceived through assisted reproductive technology (ART) showed similar asthma outcomes but had a higher risk of allergies and slightly altered lung function compared with those who were born after spontaneous conception, according to a study presented at ESHRE 2022.
Timing of maternal antibiotic administration affects infant gut microbiome
Audrey Abella, 28 Jun 2021
Maternal administration of antibiotics prior to Caesarean section (CS) disrupts infant microbial colonization, according to the findings of the MAMI* trial presented at WCPGHAN 2021.
Bioactive nutrient-enriched infant formula may enhance neurocognitive outcomes
Elaine Soliven, 22 Jun 2021
A new infant formula supplemented with bioactive nutrients — containing MFGM* components, LC-PUFAs**, and synbiotics — may improve neurocognitive function and brain development in healthy children at 6 years of age, according to the COGNIS*** study presented at WCPGHAN 2021.